For the quarter ended December 31, 2025, Karyopharm reported:
Revenue:
• Total consolidated revenue: $34.1 million in Q4 2025, up from $30.5 million in Q4 2024.
• Net product revenue (XPOVIO): $32.1 million in Q4 2025, compared with $29.3 million in Q4 2024.
• License and other revenue: $2.0 million versus $1.3 million in Q4 2024.
Expenses and Operations:
• R&D expenses: $27.7 million (down from $33.3 million).
• SG&A expenses: $22.8 million (down from $27.2 million).
• Loss from operations: $17.8 million compared with $31.3 million in Q4 2024.
Net Loss:
• Net loss: $102.2 million, or $5.71 per basic and diluted share, compared with a net loss of $30.8 million, or $3.67 per basic and diluted share, in Q4 2024.
Full-Year Results Context
For the full year 2025, the company reported:
• Annual consolidated revenue: $146.1 million, compared with $145.2 million in 2024;
• Net loss: $196.0 million, or $17.93 per basic and diluted share, compared with a net loss of $76.4 million, or $9.41 per basic share in 2024.
The figures indicate year-over-year revenue growth and an increase in net loss for both the quarter and full year.
Business & Operations Update
In its earnings release and associated materials, Karyopharm highlighted ongoing Phase 3 clinical trial progress, including the SENTRY trial in myelofibrosis and the XPORT-EC-042 trial in endometrial cancer, both on track for top-line data readouts in 2026.
The company also noted operational cost management, with reductions in R&D and SG&A expenses in Q4 2025 compared with the prior year, reflecting lower personnel-related costs and reduced commercial spending.
Equity Analyst Commentary
Institutional research summaries referenced by financial market watchers highlight the company’s revenue increase and wider net loss, along with anticipation of pivotal clinical data readouts that may influence future financial performance. Analysts have noted these results without providing specific price targets or recommendations.
Guidance & Outlook
Karyopharm’s press materials include 2026 total revenue guidance of $130 million to $150 million, with XPOVIO net product revenue guidance of $115 million to $130 million. Management also reiterated that liquidity and existing cash resources are expected to fund operations into at least the second quarter of 2026.
Key near-term company milestones to watch include top-line clinical trial data results in myelofibrosis and endometrial cancer, with scheduled readouts in 2026.
Performance Summary
• Stock move: Shares closed higher with extended session gains following the earnings release.
• Quarterly results: Total revenue of $34.1 million and net loss of $102.2 million in Q4 2025.
• Full-year context: Annual revenue of $146.1 million and higher net loss compared with 2024.